Denali Therapeutics (DNLI) Sells Priority Review Voucher for $195M

Denali Therapeutics will receive $195 million in gross proceeds from the sale of a rare pediatric disease priority review voucher awarded after the FDA approved its AVLAYAH therapy.

By the FiledFeed automated desk Jun 18, 2026 12:04 PM ET

This summary was generated by AI from the company's SEC filing and may contain errors — always verify against the primary source on SEC.gov.

The short version

Denali Therapeutics Inc. (DNLI) announced on June 18, 2026 that it has signed a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $195 million in gross proceeds. The FDA awarded the PRV to Denali following its accelerated approval in March 2026 of AVLAYAH™ (tividenofusp alfa-eknm), a treatment for Hunter syndrome designed to cross the blood-brain barrier. Denali said it plans to use the proceeds to advance its pipeline of therapies for lysosomal storage disorders and neurodegenerative diseases.

Denali Therapeutics Inc. (Nasdaq: DNLI) said it has agreed to sell a regulatory certificate — known as a Rare Pediatric Disease Priority Review Voucher (PRV) — for $195 million in gross proceeds, according to an 8-K filing (a report companies use to disclose major news) filed June 18, 2026.

What Is a Priority Review Voucher?

A PRV is a certificate awarded by the U.S. Food and Drug Administration (FDA) to drug developers who win approval for treatments targeting rare diseases in children. The holder of the voucher can use it to speed up the FDA's review of any future drug application — cutting the standard review timeline from about 12 months to 6 months — or sell it to another company that wants to use it. Selling these vouchers can generate significant cash, and Denali chose to monetize (convert to cash) the one it received.

How Denali Earned the Voucher

The FDA awarded Denali the PRV following its accelerated approval in March 2026 of AVLAYAH™ (tividenofusp alfa-eknm), an enzyme replacement therapy for Hunter syndrome (also called mucopolysaccharidosis type II, or MPS II), a rare inherited disease. According to the filing, AVLAYAH is the first FDA-approved medicine specifically designed to cross the blood-brain barrier — the protective layer separating the brain from the bloodstream — by attaching to a natural transport receptor called transferrin receptor (TfR). Most drugs cannot cross this barrier in useful amounts, making it a longstanding challenge in treating brain diseases.

Where the Money Goes

Denali said the $195 million in proceeds will be used to fund its broader pipeline of experimental therapies. Those programs include:

DNL126 for Sanfilippo syndrome type A (a rare, progressive brain disease in children)
DNL593 for a genetic form of frontotemporal dementia (a brain disease affecting behavior and language)
DNL952 for Pompe disease (a rare muscle and heart disease)
DNL628 for Alzheimer's disease

Denali also has several earlier-stage programs targeting Alzheimer's disease, Parkinson's disease, Gaucher disease, and Hurler syndrome (MPS I), among others.

"The proceeds will fuel the advancement and acceleration of our broad clinical pipeline," said Alexander Schuth, M.D., Denali's Chief Operating and Financial Officer, in the filing.

Deal Still Needs to Close

The transaction has not yet closed. It is subject to customary closing conditions, including the expiration of a required antitrust waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (a U.S. law that requires companies to notify regulators and wait before completing certain large deals). The filing did not name the buyer of the voucher.

Key facts

Denali Therapeutics (DNLI) signed a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $195 million in gross proceeds.

The FDA awarded the PRV to Denali following accelerated approval of AVLAYAH™ (tividenofusp alfa-eknm) for Hunter syndrome (MPS II) in March 2026.

AVLAYAH is described as the first FDA-approved biologic specifically designed to cross the blood-brain barrier.

Proceeds will support Denali's pipeline, including programs for lysosomal storage disorders and neurodegenerative diseases such as Alzheimer's and frontotemporal dementia.

The deal is subject to customary closing conditions, including expiration of the Hart-Scott-Rodino antitrust waiting period.

The filing was made on June 18, 2026.

Alexander Schuth, M.D., is Denali's Chief Operating and Financial Officer.

Why it matters

The $195 million PRV sale is a meaningful non-dilutive cash injection — meaning Denali raises money without issuing new shares — at a critical moment following its first commercial product approval. Hunter syndrome is a rare disease with a small patient population, so product revenue alone would be limited in the near term; this voucher sale converts a regulatory milestone into substantial runway to fund a deep pipeline of brain-targeting therapies. The proceeds could extend Denali's ability to advance multiple clinical-stage programs simultaneously without immediately needing to tap equity markets, which is a favorable outcome for existing shareholders watching cash burn.

Frequently asked

What is a Rare Pediatric Disease Priority Review Voucher?

It is a certificate awarded by the FDA to companies that win approval for treatments targeting rare diseases in children. The voucher can be used to speed up FDA review of any future drug application, or it can be sold to another company. Denali chose to sell its voucher for $195 million.

Why did Denali receive a Priority Review Voucher?

The FDA awarded Denali the PRV following its accelerated approval in March 2026 of AVLAYAH™ (tividenofusp alfa-eknm), a treatment for Hunter syndrome, which is a rare pediatric disease.

Has the $195 million deal closed yet?

Not yet, according to the filing. The transaction is subject to customary closing conditions, including the expiration of an antitrust waiting period required under the Hart-Scott-Rodino Act.

How does Denali plan to use the $195 million?

Denali said the proceeds will be used to advance its clinical pipeline, including programs for lysosomal storage disorders such as Sanfilippo syndrome and Pompe disease, and neurodegenerative diseases such as Alzheimer's and frontotemporal dementia.

What the filing reported

1.01 Entry into a Material Agreement

7.01 Regulation FD Disclosure

9.01 Financial Statements & Exhibits